NFX seeks to seed more platforms at the tech-bio intersection

With its latest fund, NFX will stick to its strategy of investing early and leaving founders in control, while growing its focus on platform companies that straddle the line between technology and biology. 

NFX, whose track record includes tech companies such as Lyft Inc. (NASDAQ:LYFT), Poshmark Inc. (NASDAQ:POSH) and Trulia LLC (NYSE:TRLA), had previously planted flags at the “tech-bio” intersection via investments in CRISPR company Mammoth Biosciences, DNA synthesizer Twist Bioscience Corp. (NASDAQ:TWST) and software company Genome Compiler Corp. Twist acquired the latter in 2016. ...